Login / Signup
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
Yifan Yang
Liming Wang
Xu Li
Shuai Zhang
Jiangyong Yu
Xin Nie
Wenbo Liu
Xiaonan Wu
Ping Zhang
Yi Li
Ailing Li
Bin Ai
Published in:
Thoracic cancer (2021)
Bevacizumab combined with EGFR-TKI significantly improves PFS and ORR in patients with advanced NSCLC, but there is no substantial difference in OS and increase the risks of serious adverse events.
Keyphrases
</>
advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
small cell lung cancer
metastatic colorectal cancer
risk assessment
climate change